Gene therapy as part of modern molecular medicine holds great promise for the treatment of both acute and chronic diseases and has the potential to bring a revolutionary era to cancer treatment. Gene therapy has been named the medicine of the future. For the past 10 years various viral and non-viral vectors have been engineered for improved gene and drug delivery. Although various diseases have been targeted, cancer therapy has been addressed to a large extent because of the straight forward approach. Delivery of toxic or immunostimulatory genes by viral and non-viral vectors has been investigated and encouraging results have been obtained in animal models. A large number of clinical trials have been conducted with some highly promising outcome. We propose that combinations of viruses with lipo-somes or polymers will solve the problem of systemic viral delivery and tumor targeting, bringing a revolution in molecular medicine and in applications of gene therapy in humans.
References
1.
BoulikasT.Status of Gene Therapy in 1997: Molecular Mechanisms, Disease Targets, and Clinical Applications. Gene Ther. Mol. Biol.1, 1–172 (1998).
2.
Choisy-RossiC.ReisdorfP.Yonisch-RouachE.The p53 Supperssor Gene: Structure, Function and Mechanism of Action. Results Probl. Cell Differ.23, 145–172 (1999).
3.
WangS. C.ZhangL.HortobagyiG. N.HungM. C.Targeting HER2: Recent Developments and Future Directions for Breast Cancer Patients. Semin. Oncol.28 (Suppl 18), 21–29 (2001).
4.
HubbersteyA. V.PavlivMParksR. J.Cancer Therapy Utilizing an Adenoviral Vector Expressing Only E1A. Cancer Gene Ther9, 321–329 (2002).
5.
PaulS.RegulierE.PoitevinY.HormannH.AcresR. B.The Combination of a Chemokine, Cytokine and TCR-based T-Cell Stimulus for Effective Gene Therapy of Cancer. Cancer. Immunol. Immunother. 51, 645–654 (2002).
6.
LundqvistA.ChoudhuryA.NagataT.AnderssonT.QuinnG.FongT.MaitlandN.PetterssonS.PaulieS.PisaP.Recombinant Adenovirus Vector Activates and Protects Human Monocyte-derived Dendritic Cells from Apoptosis. Hum. Gene Ther.13, 1541–1549 (2002).
7.
KershawM. H.WangG.WestwoodJ. A.PachynskiR. K.TiffanyH. L.MarincolaF. M.WangE.YoungH. A.MurphyP. M.HwuP.Redirecting Migration of T-Cells to Chemokine Secreted from Tumors by Genetic Modification with CXCR2. Hum. Gene Ther.13, 1971–1980 (2002).
8.
JanssensW.ChuahM. K.NaldiniL.FollenziA.CollenD.Saint-RemyJ. M.Van den DriesscheT.Efficiency of Onco-retroviral and Lentiviral Gene Transfer into Primary Mouse and Human B-lymphocytes is Pseudotype Dependent. Hum. Gene Ther.14, 263–276 (2003).
AjikiT.MurakamiT.KobayashiY.HakamataY.WangJ.InoueS.OhtsukiM.NakagawaH.KariyaY.HoshinoY.KobayashiE.Long-lasting Gene Expression by Particle-mediated Intramuscular Transfection Modified with Bupivacaine: Combinatorial Gene Therapy with IL-12 and IL-18 cDNA Against Rat Sarcoma at a Distant Site. Cancer Gene Ther.10, 318–329 (2003).
11.
LeeJ. C.ParkK. H.HanS. J.YooC. G.LeeC. T.HanS. K.ShimY. S.KimY. W.Inhibitory Effect of Adenovirus-uteroglobin Transduction on the Growth of Lung Cancer Cell Lines. Cancer Gene Ther.10, 287–293 (2003).
12.
BergR. W.FergusonP. J.VincentM. D.KoropatnickD. J.A “Combination Oligonucleotide” Antisense Strategy to Downregulate Thymidylate Synthase and Decrease Tumor Cell Growth and Drug Resistance. Cancer Gene Ther.10, 278–286 (2003).
13.
NagataJ.KijimaH.HatanakaH.AsaiS.MiyachiH.AbeY.YamazakiH.NakamuraM.WatanabeN.MineT.KondoT.Reversal of Drug Resistance Using Hammerhead Ribozymes Against Multidrug Resistance-associated Protein and Multidrug Resistance 1 Gene. Int. J. Oncol.21, 1021–1026, (2002).
14.
SchondorfT.NeumannR.BenzC.BeckerM.RiffelmannM.GohringU. J.SartoriusJ.von KonigC. H.BreidenbachM.ValterM. M.HoopmannM.Di NicolantonioF.KurbacherC. M.Cisplatin, Doxorubicin and Paclitaxel Induce mdr1 Gene Transcription in Ovarian Cancer Cell Lines. Recent Results Cancer Res.161, 111–116, (2003).
15.
ChoiK. S.LeeT. H.JungM. H.Ribozyme-mediated Cleavage of the Human Survivin mRNA and Inhibition of Antiapoptotic Function of Survivin in MCF-7 Cells. Cancer Gene Ther.10, 87–95 (2003).
LundstromK.Alphavirus Vectors for Vaccine Production and Gene Therapy. Expert Rev. Vaccines2, 447–459 (2003).
21.
CheckE.Gene Therapy: A Tragic Setback. Nature420, 116–118 (2002).
22.
RabinowtzJ. E.SamulskiJ.Adeno-associated Virus Expression Systems for Gene Transfer. Curr. Opin. Biotechnol. 9, 470–475 (1998).
23.
DavidsonB. L.SteinC. S.HethJ. A.MartinsI.KotinR. M.DerksenT. A.ZabnerJ.GhodsiA.GhioriniJ. A.Recombinant Adeno-associated Virus Type 2, 4 and 5 Vectors: Transduction of Variant Cell Types and Regions in the Mammalian Central Nervous System. Proc. Natl. Acad. Sci. USA97, 3428–3432 (2000).
24.
GaoG.-P.AlviraM. R.WangL.CalcedoR.JohnstonJ.WilsonJ. M.Novel Adeno-associated Viruses from Rhesus Monkeys as Vectors for Human Gene Therapy. Proc. Natl. Acad. Sci. USA99, 11854–11859 (2002).
25.
WendtnerC. M.KoflerD. M.TheissH. D.KurzederC.BuhmannR.SchweighoferC.ParaboL.Danhauser-RiedlS.BaumertJ.HiddemannH.HallekM.BuningH.Efficient Gene Transfer of CD40 Ligand into Primary B-CLL Cells Using Recombinant Adeno-associated Virus (rAAV) Vectors. Blood100, 1655–1661 (2002).
26.
ZavorotinskayaTTomkinsonA.MurphyJ. E.Treatment of Experimental Asthma by Long-term Gene Therapy Directed Against IL-4 and IL-13. Mol. Ther.7, 155–162 (2003).
27.
TakahashiH.HiraiY.MigitaM.SeinoY.FukudaY.SaurabaH.KaseA.KobayashiT.HashimotoY.ShimadaT.Long-term Systemic Therapy of Fabry Disease in a Knockout Mouse by Adeno-associated Virus-mediated Muscle-directed Gene Transfer. Proc. Natl. Acad. Sci. USA99, 13777–13782 (2002).
28.
MartinK. R.KleinR. L.QuigleyH. A.Gene Delivery to the Eye using Adeno-associated Viral Vectors. Methods28, 267–275 (2002).
29.
SchiednerG.MorralN.ParksR. J.WuY.KoopmansS. C.LangstonC.GrahamF. L.BeaudetA. L.KochanekS.Genomic DNA Transfer with a High-capacity Adenovirus Vector Results in Improved In Vivo Gene Expression and Decreased Toxicity. Nat. Genet.18, 180–183 (1998).
30.
BradeA. M.SzmitkoP.NgoD.LiuF. F.KlamutH. J.Heat-directed Suicide Gene Therapy for Breast Cancer. Cancer Gene Ther.10, 294–301 (2003).
31.
MiyagiT.KoshidaK.HoriO.KonakaH.KatohH.KitagawaY.MizokaA.EgawaM.OgawaS.HamadaH.NamikiM.Gene Therapy for Prostate Cancer using the Cytosine Deaminase/ uracil Phosphoribosyltransferase Suicide System. J. Gene Med.5, 30–37 (2003).
32.
ChesterJ. D.KennedyW.HallG. D.SelbyP. J.KnowlesM. A.Adenovirus-mediated Gene Therapy for Bladder Cancer: Efficient Gene Delivery to Normal and Malignant Human Urothelial Cells In Vitro and Ex Vivo. Gene Ther.10, 172–179 (2003).
33.
DirvenC.Van BeusechemV.LamfersM.GrillJ.GerritsenW.VandertW.Oncolytic Adenoviruses for Treatment of Brain Tumors. Expert Opin. Biol. Ther.2, 943–952 (2002).
34.
AndoD.KirnD.The Oncolytic Virotherapy Treatment Platform for Cancer: Unique Biological and Biosafety Points to Consider. Cancer Gene Ther.9, 1062–1067 (2002).
35.
YoonT. K.ShichinoheT.LaquerreS.KasaharaN.Selectively Replicating Adenoviruses for Oncolytic Therapy. Curr. Cancer Drug Targets1, 85–107 (2001).
36.
BerntK. M.SteinwaerderD. S.NiS.LiZ. Y.RofflerS. R.LieberA.Enzyme-activated Prodrug Therapy Enhances Tumor-specific Replication of Adenovirus Vectors. Cancer Res.62, 6089–6098 (2002).
LiljeströmP.GaroffH.A New Generation of Animal Cell Expression Vectors Based on the Semliki Forest Virus Replicon. Bio/Technology9, 1356–1361 (1991).
39.
XiongC.LevisR.ShenP.SchlesingerS.RiceC. M.HuangH. V.Sindbis Virus: An Efficient, Broad Host Range Vector for Gene Expression in Animal Cells. Science243, 1189–1191 (1989).
40.
DavisN. L.BrownK. W.JohnstonR. E.In vitro Synthesis of Infectious Venezuelan Equine Encephalitis Virus RNA from a cDNA Clone: Analysis of a Viable Deletion Mutant. Virology171, 189–204 (1989).
LundstromK.RichardsJ. G.PinkJ. R.JenckF.Efficient In Vivo Expression of a Reporter Gene in Rat Brain After Injection of Replication-deficient Semliki Forest Virus. Gene Ther. Mol. Biol.3, 15–23 (1999).
43.
ColmeneroP.ChenM.Castanos-VelezE.LiljeströmP.JondahlM.Immunotherapy with Recombinant SFV-replicons Expressing the P185A Tumor Antigen or IL-12 Induces Tumor Regression. Int. J. Cancer98, 554–560 (2002).
44.
YamanakaR.ZulloS. A.TanakaR.BleseM.XanthopoulosK. G.Enhancement of Antitumor Response in Glioma Models in Mice by Genetically Modified Dendritic Cells Pulsed with Semliki Forest Virus-mediated Complementary DNA. J. Neurosurg. 94, 478–481 (2001).
45.
ColmeneroP.LiljeströmP.JondalM.Induction of P185 Tumor Immunità by Recombinant Semliki Forest Virus Expressing P1A Gene. Gene Ther.6, 1728–1733 (1999).
46.
VeldersM. P.McElhineyS.CassettiM. C.EibenG. L.HigginsT.KovacsG. R.ElmishadA. G.KastW. M.SmithL. R.Eradication of Established Tumors by Vaccination with Venezuelan Equine Encephalitis Virus Replicon Particles Delivering Human Papillomavirus 16 E7 RNA. Cancer Res.61, 7861–7867 (2001).
47.
Asselin-PaturelC.LassauN.GuinebretiereJ.-M.ZhangJ.GayF.BexF.HallezS.Transfer of the Murine Interleukin-12 gene In Vivo by a Semliki Forest Virus Vector Induces B16 Tumor Regression Through Inhibition of Tumor Blood Vessel Formation Monitored by Doppler Ultrasonography. Gene Ther.6, 606–615 (1999).
48.
MurphyA.-M.Morris-DownesM. M.SheahanB. J.AtkinsG. J.Inhibition of Human Lung Carcinoma Cell Growth by Apoptosis Induction Using Semliki Forest Virus Recombinant Particles. Gene Ther.7, 1477–1482 (2000).
49.
MurphyA. M.SheahanB. J.AtkinsG.Induction of Apoptosis in Bcl-2-expressing Rat Prostate Cancer Cells using the Semliki Forest Virus Vector. Int. J. Cancer94, 572–578 (2001).
50.
OhnoK.SawaiK.IjimaY.LevinB.MerueloD.Cell-specific Targeting of Sindbis Virus Vectors Displaying IgG Binding Domains of Protein A. Nat. Biotechnol. 15, 763–767 (1997).
51.
LundstromK.BoulikasT.Breakthrough in Cancer Therapy: Encapsulation of Drugs and Viruses. Curr. Drug Discovery November issue, pp 19–23 (2002).
52.
KriskyD. M.Deletion of Early Genes from Herpes Simplex Virus Reduces Cytotoxicity and Permits Long-term Gene Expression in Neurons. Gene Ther.5, 1593–1603 (1998).
53.
HarlandJ.PapanastassiouV.BrownS. M.HSV1716 Persistance in Primary Human Glioma Cells In Vitro. Gene Ther.9, 1194–1198 (2002).
54.
NiranjanA.MoriuchiS.LunsfordL. D.KondziolkaD.FlickingerJ. C.FellowsW.RajendiranS.TamuraM.CohenJ. B.GloriosoJ. C.Effective Treatment of Experimental Glioblastoma by Herpes Simplex Virus type-1 Vector-mediated TNFalpha and HSV-tk Gene Transfer in Combination with Radiosurgery and Ganciclovir Administration. Mol. Ther.2, 114–120 (2000).
55.
AkkarajuG. R.HuardJ.HoffmanE. P.GoinsW. F.PruchnicR.WatkinsS. C.CohenJ. B.GloriosoJ. C.Herpes Simplex Virus Vector-mediated Dystrophin Gene Transfer and Expression in MDX Mouse Skeletal Muscle. J. Gene Med.1, 280–289 (1999).
56.
Gomez-NavarroJ.ContrerasJ. L.ArafatW.JiangX. L.KriskyD.OliginoD.MarconiT.HubbardB.GloriosoJ. C.CurielD. T.ThomasJ. M.Genetically Modified CD34+ Cells as Cellular Vehicles for Gene Delivery Into Areas of Angiogenesis in a Rhesus Model. Gene Ther.7, 43–52 (2000).
57.
BurnsJ. C.FriedmannT.DrieverW.BurrascanoM.YeeJ. K.Vesicular Stomatitis Virus G Glycoprotein Pseudotyped Retroviral Vectors: Concentration to Very High Titer and Efficient Gene Transfer into Mammalian and Nonmammalian Cells. Proc. Natl. Acad. Sci. USA90, 8033–8037 (1993).
58.
HuW.-S.PathakV. K.Design of Retroviral Vectors and Helper Cells for Gene Therapy. Pharmacol. Rev.52, 493–511 (2000).
59.
BoniniC.FerrariG.VerzelettiS.ServidaP.ZapponeE.RuggieriL.PonzoniM.RossigniS.MavilioF.TraversariC.BordignonC.HSV-TK Gene Transfer into Donor Lymphocytes for Control of Allogeneic Graft-versus-leukemia. Science276, 1719–1723 (1997).
60.
SollyS. K.TrajcevskiS.FrisenC.HolzerG. W.NelsonE.ClercB.Abordo-AbesidaE.CastroM.LowensteinP.KlatzmannD.Replicative Retroviral Vectors for Cancer Gene Therapy. Cancer Gene Ther.10, 30–39 (2003).
61.
Cavazzana-CalvoM.Hacein-BeyS.de Saint BasileG.GrossF.YvonE.NusbaumP.SelzF.HueC.CertainS.CasanovaJ. L.BoussoP.DeistF. L.FischerA.Gene Therapy of Human Severe Combined Immune Deficiency (SCID)-X1 Disease. Science288, 669–672 (2000).
62.
VignaE.NaldiniL.Lentiviral Vectors: Excellent Tools for Experimental Gene Transfer and Promising Candidates for Gene Therapy. J. Gene Med.2, 308–316 (2000).
IkedaY.CollinsM. K.RadcliffeP. A.MitrophanousK. A.TakeuchiY.Gene Transduction Efficiency in Cells of Different Species by HIV and EIAV. Gene Ther.9, 932–938 (2002).
65.
FollenziA.Efficient Gene Delivery and Targeted Expression to Hepatocytes In Vivo by Improved Lentivirus Vectors. Hum. Gene Ther.13, 243–260 (2002).
66.
IndraccoloS.HabelerW.TisatoV.StivanoL.PiovanE.ToselloV.EspositoG.Gene Transfer in Ovarian Cancer Cells: A Comparison Between Retroviral and Lentiviral Vectors. Cancer Res.62, 6099–6107 (2002).
67.
KordowerJ. H.Neurodegeneration Prevented by Lentiviral Vector Delivery of GDNF in Primate Models of Parkinson's Disease. Science290, 767–773 (2000).
68.
KwakH.HonigH.KaufmannH. L.Poxviruses as Vectors for Cancer Immunotherapy. Curr. Opin. Drug Discov. Devel.6, 161–168 (2003).
69.
ZehH. J.BartlettD. L.Development of a Replication-selective, Oncolytic Poxvirus for the Treatment of Human Cancers. Cancer Gene Ther.9, 1001–1012 (2002).
70.
MastrangeloM. J.LattimeE. C.Virotherapy Clinical Trials for Regional Disease: In Situ Immune Modulation using Recombinant Poxvirus Vectors. Cancer Gene Ther.9, 1013–1021 (2002).
71.
DrexlerI.AntunesE.SchmitzM.WölfelT.HuberC.ErfleV.RieberP.TheobaldiM.SutterG.Modified Vaccinia Virus Ankara for Delivery of Human Tyrosinase as Melanoma-associated Antigen: Induction of Tyrosinase- and Melanoma-specific Human Leukocyte Antigen A* 0201-restricted Cytotoxic T-Cells In Vitro and In Vivo. Cancer Res.59, 4955–4963 (1999).
72.
IkonomouL.SchneiderY. J.AgathosS. N.Insect Cell Culture for Industrial Production of Recombinant Proteins. Appl. Microbiol. Biotechnol., in press, (2003).
73.
LehtolainenP.TyynelaKKannastoJ.AirenneK. J.Yla-HerttualaS.Baculoviruses Exhibit Restricted Cell Type Specificity in Rat Brain: Comparison of Baculovirus- and Adenovirus-mediated Intracerebral Gene Transfer In Vivo. Gene Ther.9, 1693–1699 (2002).
ZeisigR.RessAFichtnerIWaltherW.Lipoplexes with Alkylphospholipid as New Helper Lipid for Efficient In Vitro and In Vivo Gene Transfer in Tumor Therapy. Cancer Gene Ther.10, 302–311 (2003).
76.
StopeckA. T.JonesA.HershE. M.ThompsonJ. A.Phase II Study of Direct Intralesional Gene Transfer of Allovectin-7, an HLA-B7/b2-microglobulin DNA-liposome Complex in Patients with Metastatic Melanoma. Clin. Cancer Res.7, 2285–2291 (2001).
77.
StopeckA. T.HershE. M.AkporiayeE. T.HarrisD. T.Phase I Study of Direct Gene Transfer of an Allogeneic Histocompatibility Antigen, HLA-B7, In Patients with Metastatic Melanoma. J. Clin. Oncol.15, 341–349 (1997).
78.
D'UrsoC. M.WangZ. G.CaoY.TatakeR.ZeffR. A.FerroneS.Lack of HLA Class I Antigen Expression by Cultured Melanoma Cells FO-1 Due to a Defect in B2m Gene Expression. J. Clin. Investig.87, 284–292 (1991).
79.
IsekiG.SugawaraMSaitohN.MiyazakiK.The Transport Mechanism of Organic Cations and Their Zwitterionic Derivatives Across Rat Intestinal Brush-border Membrane. 1. Binding Characteristics to the Bio- and Lipid-membranes. Biochim. Biophys. Acta1146, 121–126 (1993).
80.
AlexandridousS.MangeF.FoissyA.Surface Characterization of Oil-containing Polytherephtalamide Microcapsules Prepared by Interfacial Polymerization. J. Microencapsul. 18, 767–781 (2001).
81.
RittnerK.BenaventeA.Bompard-SorletA.HeitzF.New Basic Membrane-destabilizing Peptides for Plasmid-based Gene Delivery In Vitro and In Vivo. Mol. Ther.5, 104–114 (2002).
82.
MartinF.BoulikasT.The Challenge of Liposomes in Gene Therapy. Gene Ther. Mol. Biol.1, 173–214 (1998).
83.
AllenT. M.ChonnA.Large Unilamellar Liposomes with Low Uptake into the Reticuloendothelial System. FEBS Lett.223, 42–46 (1987).
84.
GabizonA.ShiotaR.PapahadjopoulosD.Pharmacokinetics and Tissue Localization of Doxorubicin Encapsulated in Stable Liposomes with Long Circulation Times. J. Natl. Cancer Inst.81, 1484–1488 (1989).
85.
BeauchampC. O.GoniasS. L.MenapaceD. P.PizzoS. V.A New Procedure for the Synthesis of Polyethylene Glycol-protein Adducts; Effects on Function, Receptor Recognition, and Clearance of Superoxide Dismutase, Lactoferrin, and Alpha 2-macroglobulin. Anal. Biochem. 131, 25–33 (1983).
86.
GabizonA.PapahadjopoulosD.Liposome Formulations with Prolonged Circulation Time in Blood and Enhanced Uptake by Tumors. Proc. Natl. Acad. Sci. USA85, 6949–6953 (1988).
87.
KlibanovA. L.MaruyamaK.TorchilinV. P.HuangL.Amphipathic Polyethyleneglycols Effectively Prolong the Circulation Time of Liposomes. FEBS Lett.268, 235–237 (1990).
88.
LasicD. D.MartinF. J.GabizonAHuangS. K.PapahadjopoulosD.Sterically Stabilized Liposomes: A Hypothesis on the Molecular Origin to the Extended Circulation Times. Biochim. Biophys. Acta1070, 187–192 (1991).
89.
TorchilinV. P.KlibanovA. L.HuangL.O'DonnellS.NossiffN. D.KhawB. A.Targeted Accumulation of Polyethylene Glycolcoated Immunoliposomes in Infarcted Rabbit Myocardium. FASEB J.6, 2716–2719 (1992).
90.
BoulikasT.StathopoulosG. P.DeliconstantinosG.RigatosS.DarliE.ViliotouV.VougioukaM.A New Liposomal Cisplatin Lacks Renal Toxicity and Other Serious Adverse Reactions: A Phase I Study. (Submitted) (2003).
91.
BoulikasT.Anticancer Activity of a Novel Liposomal Cisplatin (Lipoplatin) and Tumor Targeting with Liposomal Genes in Mouse Xenografts. Submitted (2003).
AbrahamsJ. M.SongC.DeFeliceS.GradyM. S.DiamondS. L.LevyR. J.Endovascular Microcoil Gene Delivery Using Immobilized Anti-adenovirus Antibody for Vector Tethering. Stroke33, 1376–1382 (2002).
94.
BrickelmaierM.CarmilloA.GoelzS.BarsoumJ.QinX. Q.Cytotoxicity of Combinations of IFN-beta and Chemotherapeutic Drugs. J. Interferon Cytokine Res.22, 873–80 (2002).
95.
KigawaJ.SatoS.ShimadaM.TakahashiM.ItamochiH.KanamoriY.TerakawaN.p53 Gene Status and Chemosensitivity in Ovarian Cancer. Hum. Cell14, 165–71 (2002).
96.
SongK.FukushimaP.SethP.SinhaB. K.Role of p53 and Apoptosis in Sensitization of Cis-diamminedichloroplatinum Antitumor Activity by Interleukin-1 in Ovarian Carcinoma Cells. Int. J. Oncol.12, 299–304 (1998).
97.
BiesmaB.van KralingenK. W.van LeenR. W.KosterM. C.PostmusP. E.Recombinant Human Interleukin-3 Administered Concomitantly with Chemotherapy in Patients with Relapsed Small Cell Lung Cancer. J. Exp. Ther. Oncol.2, 47–52 (2002).
98.
TimiryasovaT. M.GridleyD. S.ChenB.AndresM. L.Dutta-RoyR.MillerG.BayetaE. J. M.FodorI.Radiation Enhances the Anti-tumor Effects of Vaccinia-p53 Gene Therapy in Glioma. Technol. Cancer Res. Treatment2, 223–235 (2003).
BullerR. E.ShahinM. S.HorowitzJ. A.RunnebaumI. B.MahavniV.PetrauskasS.KreienbergR.KarlanB.SlamonD.PegramM.Long Term Follow-up of Patients with Recurrent Ovarian Cancer After Ad p53 Gene Replacement with SCH 58500. Cancer Gene Ther.9, 567–572 (2002a).
101.
BullerR. E.RunnebaumI. B.KarlanB. Y.HorowitzJ. A.ShahinM.BuekersT.PetrauskasS.KreienbergR.SlamonD.PegramM.A Phase I/II Trial of rAd/p53 (SCH 58500) Gene Replacement in Recurrent Ovarian Cancer. Cancer Gene Ther.9, 553–566 (2002b).
102.
YooG. H.HungM. C.Lopez-BeresteinG.LaFolletteS.EnsleyJ. F.CareyM.BatsonE.ReynoldsT. C.MurrayJ. L.Phase I Trial of Intratumoral Liposome E1A Gene Therapy in Patients with Recurrent Breast and Head and Neck Cancer. Clin. Cancer Res.7, 1237–1245 (2001).
103.
FlotteT. R.ZeitlinP. L.ReynoldsT. C.HealdA. L.PedersenP.BeckS.ConradC. K.Phase I Trial of Intranasal and Endobronchial Administration of a Recombinant Adeno-associated Virus Serotype 2 (rAAV2)-CFTR Cector in Adult Cystic Fibrosis Patients: A Two-part Clinical Study. Hum. Gene Ther.14, 1079–1088 (2003).
